Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 10/20 | 1.00 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376701 | 1.00 | USP9X (1.00) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL16647263 | 1.00 | USP9X (1.00) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL16647252 | 0.93 | USP9X (0.88) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL18017557 | 0.93 | USP9X (0.86) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL18017555 | 0.93 | USP9X (0.86) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL16647236 | 0.90 | USP9X (0.82) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL23171163 | 0.87 | USP9X (0.76) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL18017556 | 0.86 | USP9X (0.75) | USP9XUSP24KMT2ACACNA1BAPBA1 | |
| SCHEMBL18017567 | 0.85 | USP9X (0.74) | USP9XUSP24KMT2AUCHL1USP5 | |
| SCHEMBL18017565 | 0.85 | USP9X (0.73) | USP9XUSP24KMT2AGAAUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055310-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-03-31 | — | — | EP | disclosed |
| US-9868736-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160237082-A1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237082-A1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | USP1, UCHL1, USP2 | USP9X 33/4885USP24 29/4885KMT2A 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.